I型干扰素内型驱动儿童起病SLE不同临床轨迹:系统免疫学新方法
该研究对74例儿童起病SLE年轻女性及20例匹配对照进行多组学分析,基于IFN-I读数将患者分为IFN-high(65%)与IFN-low(35%)两组,独立于疾病活动度;IFN-high组IFNα升高、淋巴细胞减少、对anifrolumab体外反应更强,LAMP3为稳定生物标志物;整合数据定义6种IFN驱动内型,其IFN-I活性、器官损伤、复发负担及激素暴露轨迹不同。
要点
- cSLE患者可分IFN-high与IFN-low两群,不依赖疾病活动度。
- LAMP3是IFN-high状态的稳定可重复生物标志物。
- 6种IFN驱动内型在器官损伤和复发轨迹上存在差异。
核心结论
- 多层次IFN分析揭示了IFN-high患者的潜在临床生物标志物,并定义了具有临床意义的内型,支持系统免疫学与生物标志物指导的个体化治疗策略。
研究设计与样本
- 研究纳入74例儿童起病SLE年轻女性及20例匹配对照,采用PBMC RNA测序、SIMOA测IFNα、IFN-I荧光素酶报告细胞、光谱流式及Olink蛋白质组学(ELISA验证),并按IFN-I读数分组进行纵向轨迹分析,在独立验证队列测试聚类可重复性。
主要发现
- 基因表达分析显示cSLE中显著上调基因富集于IFN-I通路。
- 患者聚类为IFN-high(65%)与IFN-low(35%)两组,独立于疾病活动度。
- IFN-high患者IFNα升高、报告细胞活性增强、淋巴细胞计数降低,且体外对anifrolumab反应更强。
- LAMP3成为IFN-high状态的稳定可重复生物标志物。
- T细胞与浆细胞样树突状细胞对IFN-I体外最敏感,功能标志谱不同;整合转录组、蛋白质组与细胞数据定义6种IFN驱动内型,其IFN-I活性、器官损伤、复发负担及激素暴露的纵向轨迹不同。
临床怎么用
- 可依据IFN-I读数(如LAMP3)识别IFN-high患者,为生物标志物指导的个体化治疗提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Childhood-onset systemic lupus erythematosus (cSLE) is a severe autoimmune disease with significant morbidity and enhanced type I interferon (IFN-I) signalling, potentially contributing to its aggressive clinical course. This study aimed to deliver the most comprehensive multiomic characterisation of IFN-I signalling in cSLE, defining its heterogeneity at transcriptomic, proteomic, and cellular levels, and linking these profiles to detailed clinical trajectories. METHODS: We profiled 74 young females with cSLE and 20 matched controls using RNA-sequencing of peripheral blood mononuclear cells, single molecule array (SIMOA) for IFNα quantification, IFN-I luciferase reporter cells, spectral flow cytometry, and Olink proteomics (validated by enzyme-linked immunosorbent assay, (ELISA)). Clinical data were assessed in endotype groups based on IFN-I readouts with longitudinal trajectory analysis, and clustering reproducibility was tested in independent validation cohorts. RESULTS: Gene expression analysis revealed significantly upregulated genes in cSLE with strong IFN-I pathway enrichment. Patients clustered into IFN-high (65%) and IFN-low (35%) groups, independent of disease activity. IFN-high patients showed elevated IFNα, reporter cell activity, reduced lymphocyte counts, and greater in vitro response to anifrolumab. LAMP3 emerged as a stable and reproducible biomarker of IFN-high status. T cells and plasmacytoid dendritic cells were most sensitive to IFN-I ex vivo, with distinct functional marker profiles. Integrated transcriptomic, proteomic, and cellular data defined 6 IFN-driven endotypes with unique immune signatures and clinical phenotypes. Endotypes differed in IFN-I activity, organ damage, flare burden, and corticosteroid exposure with divergent longitudinal trajectories. CONCLUSIONS: Multilevel IFN profiling revealed an important biomarker of IFN-high patients for potential use in clinical practice, immune lineage-specific responses, and clinically meaningful endotypes, supporting systems immunology approaches and biomarker-guided personalised treatment strategies.
引用
- Cross H, Peng J, McDonnell T, et al. Type I interferon endotypes drive divergent clinical trajectories in childhood-onset SLE uncovered through a novel systems immunology approach. Ann Rheum Dis. 2026. PMID: 41539892. doi:10.1016/j.ard.2025.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。